Explanation
This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are
presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.
"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.
miRNA-gene regulations
| Num | microRNA | Gene | miRNA log2FC | miRNA pvalue | Gene log2FC | Gene pvalue | Interaction | Correlation beta | Correlation P-value | PMID | Reported in cancer studies |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | hsa-miR-34a-5p | ACSL4 | 1.9 | 0 | -0.41 | 0.0792 | miRNAWalker2 validate; MirTarget; miRNATAP | -0.13 | 0.00399 | NA | |
| 2 | hsa-miR-34a-5p | ADAM22 | 1.9 | 0 | -1.12 | 0.02589 | MirTarget; miRNATAP | -0.32 | 0.00075 | NA | |
| 3 | hsa-miR-34a-5p | ADAMTS2 | 1.9 | 0 | -0.77 | 0.15763 | MirTarget | -0.53 | 0 | NA | |
| 4 | hsa-miR-34a-5p | ADARB1 | 1.9 | 0 | -1.93 | 0 | miRNAWalker2 validate | -0.48 | 0 | NA | |
| 5 | hsa-miR-34a-5p | AFAP1L2 | 1.9 | 0 | 0.06 | 0.85809 | miRNAWalker2 validate | -0.18 | 0.00406 | NA | |
| 6 | hsa-miR-34a-5p | AFF4 | 1.9 | 0 | -0.82 | 0 | miRNATAP | -0.11 | 0.00024 | NA | |
| 7 | hsa-miR-34a-5p | AHNAK | 1.9 | 0 | -1.66 | 0 | miRNAWalker2 validate | -0.3 | 0 | NA | |
| 8 | hsa-miR-34a-5p | AKAP13 | 1.9 | 0 | -1.15 | 0 | mirMAP | -0.21 | 0 | NA | |
| 9 | hsa-miR-34a-5p | AKAP6 | 1.9 | 0 | -3.34 | 0 | MirTarget | -0.91 | 0 | NA | |
| 10 | hsa-miR-34a-5p | ALCAM | 1.9 | 0 | -0.73 | 0.05647 | MirTarget; miRNATAP | -0.18 | 0.01418 | NA | |
| 11 | hsa-miR-34a-5p | ALDH1L2 | 1.9 | 0 | -1.12 | 0.02448 | MirTarget | -0.67 | 0 | NA | |
| 12 | hsa-miR-34a-5p | AMOTL2 | 1.9 | 0 | -1.01 | 0.00015 | MirTarget | -0.31 | 0 | NA | |
| 13 | hsa-miR-34a-5p | ANK2 | 1.9 | 0 | -4.32 | 0 | MirTarget; miRNATAP | -0.92 | 0 | NA | |
| 14 | hsa-miR-34a-5p | ANP32B | 1.9 | 0 | 0.07 | 0.67073 | miRNATAP | -0.12 | 7.0E-5 | NA | |
| 15 | hsa-miR-34a-5p | AP1S2 | 1.9 | 0 | -1.31 | 0 | MirTarget | -0.43 | 0 | NA | |
| 16 | hsa-miR-34a-5p | AR | 1.9 | 0 | -3.3 | 0 | MirTarget | -0.29 | 0.02683 | 24349627; 22347519; 21343391; 25920548; 25797256; 23145211 | In this study we found loss of miR-34a which targets AR in PCa tissue specimens especially in patients with higher Gleason grade tumors consistent with increased expression of AR; Most importantly BR-DIM intervention in PCa patients prior to radical prostatectomy showed reexpression of miR-34a which was consistent with decreased expression of AR PSA and Notch-1 in PCa tissue specimens; PCa cells treated with BR-DIM and 5-aza-dC resulted in the demethylation of miR-34a promoter concomitant with inhibition of AR and PSA expression in LNCaP and C4-2B cells; These results suggest for the first time epigenetic silencing of miR-34a in PCa which could be reversed by BR-DIM treatment and thus BR-DIM could be useful for the inactivation of AR in the treatment of PCa.This corrects the article on p;In this study we found loss of miR-34a which targets AR in PCa tissue specimens especially in patients with higher Gleason grade tumors consistent with increased expression of AR; Most importantly BR-DIM intervention in PCa patients prior to radical prostatectomy showed re-expression of miR-34a which was consistent with decreased expression of AR PSA and Notch-1 in PCa tissue specimens; PCa cells treated with BR-DIM and 5-aza-dC resulted in the demethylation of miR-34a promoter concomitant with inhibition of AR and PSA expression in LNCaP and C4-2B cells;In particular analysis of clinical prostate cancers confirmed a negative correlation of miR-34a and miR-34c expression with AR levels;To explore further the possible role of miRNAs in the AR pathway LNCaP cell line was treated with 5α-dihydrotestosterone and flutamide showing alteration in miRNAs expression especially miR-34a which was significantly underexpressed after treatment with high doses of 5α-dihydrotestosterone; Our data support a role for miRNAs especially miR-371 and miR-34a in the complex disarrangement of AR signaling pathway and in the behavior of PC;Repression of miR-34a a known AR-targeting miRNA contributes AR expression by XRN1;Inactivation of AR and Notch 1 signaling by miR 34a attenuates prostate cancer aggressiveness; We found that over-expression of miR-34a led to reduced expression of AR PSA and Notch-1; These findings suggest that the loss of miR-34a is directly linked with up-regulation of AR and Notch-1 both of which are highly expressed in PCa and thus finding innovative approaches by which miR-34a expression could be up-regulated will have a huge impact on the treatment of PCa especially for the treatment of mCRPC |
| 17 | hsa-miR-34a-5p | ARHGAP1 | 1.9 | 0 | -0.88 | 0 | miRNAWalker2 validate; MirTarget; miRNATAP | -0.18 | 0 | NA | |
| 18 | hsa-miR-34a-5p | ASB1 | 1.9 | 0 | -0.87 | 0 | MirTarget; miRNATAP | -0.16 | 0 | NA | |
| 19 | hsa-miR-34a-5p | ASTN1 | 1.9 | 0 | -2.34 | 2.0E-5 | MirTarget | -0.25 | 0.01797 | NA | |
| 20 | hsa-miR-34a-5p | ASXL2 | 1.9 | 0 | -0.51 | 0.09339 | MirTarget | -0.27 | 0 | NA | |
| 21 | hsa-miR-34a-5p | AXIN2 | 1.9 | 0 | -1.7 | 6.0E-5 | miRNAWalker2 validate; miRTarBase | -0.32 | 9.0E-5 | 23624843 | p53 regulates nuclear GSK 3 levels through miR 34 mediated Axin2 suppression in colorectal cancer cells; Exogenous miR-34a decreases Axin2 UTR-reporter activity through multiple binding sites within the 5' and 3' UTR of Axin2; Further RNA transcripts of miR-34 target were correlated with Axin2 in clinical data set of colorectal cancer patients |
| 22 | hsa-miR-34a-5p | AXL | 1.9 | 0 | -1.77 | 0 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.54 | 0 | 26667302; 21814748; 25895459 | Negative feedback regulation of AXL by miR 34a modulates apoptosis in lung cancer cells; To clarify the role of miRNAs in this regulation loop approaches using bioinformatics and molecular techniques were applied revealing that miR-34a may target the 3' UTR of AXL mRNA to inhibit AXL expression; Therefore we propose that AXL is autoregulated by miR-34a in a feedback loop; this may provide a novel opportunity for developing AXL-targeted anticancer therapies;We identified human miR-34a expression as being >3-fold down from its median expression value across all cell lines in MDA-MB-231 cells and identified AXL as a putative mRNA target using multiple miRNA/target prediction algorithms; In reporter assays miR-34a binds to its putative target site within the AXL 3'UTR to inhibit luciferase expression; Finally we present an inverse correlative trend in miR-34a and AXL expression for both cell line and patient tumor samples;MiR 34a suppresses ovarian cancer proliferation and motility by targeting AXL; Overexpression of miR-34a led to the inhibition of AXL expression indicating that AXL is a target gene for miR-34a; Our data suggest that miR-34a may function as a tumor suppressor through repression of oncogenic AXL in ovarian cancer |
| 23 | hsa-miR-34a-5p | BCL2 | 1.9 | 0 | -2.02 | 0 | miRNAWalker2 validate; miRTarBase | -0.31 | 0 | 24565525; 23155233; 24444609; 20687223; 22623155; 24988056; 18803879; 19714243; 25053345; 20433755; 21399894; 22964582; 23862748 | In vitro and in vivo experiments showed that miR-34a and DOX can be efficiently encapsulated into HA-CS NPs and delivered into tumor cells or tumor tissues and enhance anti-tumor effects of DOX by suppressing the expression of non-pump resistance and anti-apoptosis proto-oncogene Bcl-2;The miR-34a expression levels in cells after irradiation at 30 and 60 Gy were 0.17- and 18.7-times the BCL2 and caspase-9 expression levels respectively;Functional analyses further indicate that restoration of miR-34a inhibits B cell lymphoma-2 Bcl-2 protein expression to withdraw the survival advantage of these resistant NSCLC cells;Thus in PC3PR cells reduced expression of miR-34a confers paclitaxel resistance via up-regulating SIRT1 and Bcl2 expression; MiR-34a and its downstream targets SIRT1 and Bcl2 play important roles in the development of paclitaxel resistance all of which can be useful biomarkers and promising therapeutic targets for the drug resistance in hormone-refractory prostate cancer;MiR 34a inhibits proliferation and migration of breast cancer through down regulation of Bcl 2 and SIRT1; In this study we aimed to determine the effect of miR-34a on the growth of breast cancer and to investigate whether its effect is achieved by targeting Bcl-2 and SIRT1; Bcl-2 and SIRT1 as the targets of miR-34a were found to be in reverse correlation with ectopic expression of miR-34a;Target analysis indicated that micro RNA miR-34a directly regulates Bcl-2 and miR-34a overexpression decreased Bcl-2 protein level in gastric cancer cells; We also found that luteolin upregulates miR-34a expression and downregulates Bcl-2 expression; Based on these results we can draw the conclusion that luteolin partly decreases Bcl-2 expression through upregulating miR-34a expression;miR-34 targets Notch HMGA2 and Bcl-2 genes involved in the self-renewal and survival of cancer stem cells; Human gastric cancer cells were transfected with miR-34 mimics or infected with the lentiviral miR-34-MIF expression system and validated by miR-34 reporter assay using Bcl-2 3'UTR reporter; Human gastric cancer Kato III cells with miR-34 restoration reduced the expression of target genes Bcl-2 Notch and HMGA2; Bcl-2 3'UTR reporter assay showed that the transfected miR-34s were functional and confirmed that Bcl-2 is a direct target of miR-34; The mechanism of miR-34-mediated suppression of self-renewal appears to be related to the direct modulation of downstream targets Bcl-2 Notch and HMGA2 indicating that miR-34 may be involved in gastric cancer stem cell self-renewal/differentiation decision-making;Among the target proteins regulated by miR-34 are Notch pathway proteins and Bcl-2 suggesting the possibility of a role for miR-34 in the maintenance and survival of cancer stem cells; Our data support the view that miR-34 may be involved in pancreatic cancer stem cell self-renewal potentially via the direct modulation of downstream targets Bcl-2 and Notch implying that miR-34 may play an important role in pancreatic cancer stem cell self-renewal and/or cell fate determination;Manipulating miR-34a in prostate cancer cells confirms that this miRNA regulates BCL-2 and may in part regulate response to docetaxel;For instance miR-34a up-regulation corresponded with a down-regulation of BCL2 protein; Treating Par-4-overexpressing HT29 cells with a miR-34a antagomir functionally reversed both BCL2 down-regulation and apoptosis by 5-FU;Quantitative PCR and western analysis confirmed decreased expression of two genes BCL-2 and CCND1 in docetaxel-resistant cells which are both targeted by miR-34a;Tumors harvested from these lungs have elevated levels of oncogenic miRNAs miR-21 and miR-155; are deficient for p53-regulated miRNAs; and have heightened expression of miR-34 target genes such as Met and Bcl-2;MicroRNA 34a targets Bcl 2 and sensitizes human hepatocellular carcinoma cells to sorafenib treatment; HCC tissues with lower miR-34a expression displayed higher expression of Bcl-2 protein than those with high expression of miR-34a; therefore an inverse correlation is evident between the miR-34a level and Bcl-2 expression; Bioinformatics and luciferase reporter assays revealed that miR-34a binds the 3'-UTR of the Bcl-2 mRNA and represses its translation; Western blotting analysis and qRT-PCR confirmed that Bcl-2 is inhibited by miR-34a overexpression; Functional analyses indicated that the restoration of miR-34a reduced cell viability promoted cell apoptosis and potentiated sorafenib-induced apoptosis and toxicity in HCC cell lines by inhibiting Bcl-2 expression |
| 24 | hsa-miR-34a-5p | BIRC3 | 1.9 | 0 | -1.15 | 0.00716 | miRNAWalker2 validate | -0.22 | 0.0078 | NA | |
| 25 | hsa-miR-34a-5p | BMP1 | 1.9 | 0 | 0.19 | 0.45337 | mirMAP | -0.15 | 0.0018 | NA | |
| 26 | hsa-miR-34a-5p | BNC2 | 1.9 | 0 | -2.95 | 0 | miRNATAP | -0.8 | 0 | NA | |
| 27 | hsa-miR-34a-5p | C17orf51 | 1.9 | 0 | -0.68 | 0.02254 | mirMAP | -0.25 | 1.0E-5 | NA | |
| 28 | hsa-miR-34a-5p | C1orf21 | 1.9 | 0 | -1.51 | 0 | mirMAP | -0.22 | 0 | NA | |
| 29 | hsa-miR-34a-5p | C3orf70 | 1.9 | 0 | -2.6 | 0 | miRNATAP | -0.47 | 0 | NA | |
| 30 | hsa-miR-34a-5p | C6orf106 | 1.9 | 0 | -0.16 | 0.26914 | miRNATAP | -0.1 | 0.00011 | NA | |
| 31 | hsa-miR-34a-5p | CACHD1 | 1.9 | 0 | -1.73 | 0 | MirTarget | -0.41 | 0 | NA | |
| 32 | hsa-miR-34a-5p | CACNA1C | 1.9 | 0 | -2.53 | 0 | MirTarget | -0.48 | 0 | NA | |
| 33 | hsa-miR-34a-5p | CALD1 | 1.9 | 0 | -2.47 | 0 | miRNAWalker2 validate | -0.73 | 0 | NA | |
| 34 | hsa-miR-34a-5p | CAMK2B | 1.9 | 0 | 0.67 | 0.19425 | mirMAP | -0.26 | 0.00749 | NA | |
| 35 | hsa-miR-34a-5p | CAPN6 | 1.9 | 0 | -3.48 | 0 | miRNATAP | -0.83 | 0 | NA | |
| 36 | hsa-miR-34a-5p | CCDC50 | 1.9 | 0 | -0.78 | 0 | miRNATAP | -0.18 | 0 | NA | |
| 37 | hsa-miR-34a-5p | CD44 | 1.9 | 0 | -0.8 | 0.04276 | miRNAWalker2 validate; miRTarBase | -0.28 | 0.00023 | 25572695; 24423412; 25551284; 25044638; 21240262; 26231042; 27497057; 23314380 | The c-Myc and CD44 were confirmed as direct targets of miR-34a in EJ cell apoptosis induced by PRE;Furthermore we identified CD44 as being targeted by miR-34a in MIBC cells following cisplatin treatment and increased CD44 expression could efficiently reverse the effect of miR-34a on MIBC cell proliferation colongenic potential and chemosensitivity; Cisplatin-based chemotherapy induced demethylation of miR-34a promoter and increased miR-34a expression which in turn sensitized MIBC cells to cisplatin and decreased the tumorigenicity and proliferation of cancer cells that by reducing the production of CD44;MicroRNA 34a functions as an anti metastatic microRNA and suppresses angiogenesis in bladder cancer by directly targeting CD44; In this study we focus on it that microRNA-34a functions as an anti-metastatic microRNA and suppress angiogenesis in bladder cancer by directly targeting CD44; Our study defines a major metastasis and angiogenesis suppressive role for mir-34a a microRNA functions as a tumor suppressor in bladder cancer by directly targeting CD44 which would be helpful as a therapeutic approach to block bladder cancer metastasis;Nanocomplex-assisted delivery of miR-34a induces cell apoptosis and suppresses migration proliferation and tumor growth of breast cancer cells via targeting CD44 and a Notch-1-signaling pathway;The microRNA miR 34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44; We identified and validated CD44 as a direct and functional target of miR-34a and found that CD44 knockdown phenocopied miR-34a overexpression in inhibiting prostate cancer regeneration and metastasis;Registered report: the microRNA miR 34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44; Tumors with exogenous miR-34a showed reduced levels of CD44 expression Figure 4A and mutation of two putative miR-34a binding sites in the CD33 3' UTR partially abrogated signal repression in a luciferase assay Figure 4D;Nanovesicle mediated systemic delivery of microRNA 34a for CD44 overexpressing gastric cancer stem cell therapy; MicroRNA-34a miR-34a is a promising candidate for CD44 repression-based cancer therapy as it has been reported to inhibit proliferation metastasis and survival of CD44-positive CSCs; Here we used nanovesicles containing PLI/miR complexes NVs/miR to systemically deliver miR-34a and induce miR-34a-triggered CD44 suppression in orthotopically and subcutaneously implanted tumors in nude mice;miR 34a inhibits the metastasis of osteosarcoma cells by repressing the expression of CD44; The ectopic overexpression of miR-34a significantly inhibited the migration and invasive ability of osteosarcoma cells by repressing the expression of CD44; These data suggest that miR-34a plays a tumor suppressor role in the metastasis of osteosarcoma cells by repressing the expression of CD44; Therefore it can be concluded that through the inhibition of CD44 expression levels miR-34a plays a significant role in the migration and invasion of osteosarcoma cells |
| 38 | hsa-miR-34a-5p | CD47 | 1.9 | 0 | -0.16 | 0.4808 | miRNATAP | -0.2 | 0 | NA | |
| 39 | hsa-miR-34a-5p | CDC5L | 1.9 | 0 | -0.01 | 0.91454 | miRNAWalker2 validate | -0.1 | 2.0E-5 | NA | |
| 40 | hsa-miR-34a-5p | CDK6 | 1.9 | 0 | -0.77 | 0.06479 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.52 | 0 | 21702042; 26104764 | Molecular analyses identified Cdk6 and sirtuin SIRT-1 as being targeted by miR-34a in MI-TCC cells however inhibition of Cdk6 and SIRT-1 was not as effective as pre-miR-34a in mediating chemosensitization;The expression of microRNA 34a is inversely correlated with c MET and CDK6 and has a prognostic significance in lung adenocarcinoma patients; We found significant inverse correlations between miR-34a and c-MET R = -0.316 P = 0.028 and CDK6 expression R = -0.4582 P = 0.004 |
| 41 | hsa-miR-34a-5p | CDKN1C | 1.9 | 0 | -1.45 | 4.0E-5 | miRNATAP | -0.28 | 3.0E-5 | NA | |
| 42 | hsa-miR-34a-5p | CDKN2C | 1.9 | 0 | 0.23 | 0.43313 | miRNAWalker2 validate | -0.22 | 6.0E-5 | NA | |
| 43 | hsa-miR-34a-5p | CDON | 1.9 | 0 | -2.61 | 0 | miRNAWalker2 validate | -0.69 | 0 | NA | |
| 44 | hsa-miR-34a-5p | CEBPB | 1.9 | 0 | -0.38 | 0.12583 | miRNAWalker2 validate | -0.11 | 0.02632 | NA | |
| 45 | hsa-miR-34a-5p | CELF2 | 1.9 | 0 | -3.05 | 0 | miRNATAP | -0.63 | 0 | NA | |
| 46 | hsa-miR-34a-5p | CEP170 | 1.9 | 0 | -0.11 | 0.58268 | miRNAWalker2 validate | -0.25 | 0 | NA | |
| 47 | hsa-miR-34a-5p | CHM | 1.9 | 0 | -0.35 | 0.02247 | MirTarget | -0.15 | 0 | NA | |
| 48 | hsa-miR-34a-5p | CKAP5 | 1.9 | 0 | 0.47 | 0.00244 | miRNAWalker2 validate | -0.11 | 0.00011 | NA | |
| 49 | hsa-miR-34a-5p | CLOCK | 1.9 | 0 | -0.51 | 0.03689 | MirTarget | -0.2 | 1.0E-5 | NA | |
| 50 | hsa-miR-34a-5p | CNST | 1.9 | 0 | -0.93 | 0 | MirTarget | -0.15 | 0 | NA | |
| 51 | hsa-miR-34a-5p | CNTN2 | 1.9 | 0 | -3.83 | 0 | MirTarget; miRNATAP | -0.54 | 0 | NA | |
| 52 | hsa-miR-34a-5p | CNTNAP1 | 1.9 | 0 | -1.47 | 0 | MirTarget; miRNATAP | -0.36 | 0 | NA | |
| 53 | hsa-miR-34a-5p | CNTNAP2 | 1.9 | 0 | -1.31 | 0.11505 | miRNATAP | -0.67 | 2.0E-5 | NA | |
| 54 | hsa-miR-34a-5p | COL12A1 | 1.9 | 0 | 0.61 | 0.13434 | MirTarget; miRNATAP | -0.28 | 0.00031 | NA | |
| 55 | hsa-miR-34a-5p | COL5A2 | 1.9 | 0 | 0.19 | 0.64093 | MirTarget | -0.41 | 0 | NA | |
| 56 | hsa-miR-34a-5p | CORO1C | 1.9 | 0 | -1.12 | 0 | MirTarget; miRNATAP | -0.39 | 0 | NA | |
| 57 | hsa-miR-34a-5p | CPEB2 | 1.9 | 0 | -1.81 | 0 | miRNATAP | -0.29 | 0 | NA | |
| 58 | hsa-miR-34a-5p | CPEB3 | 1.9 | 0 | -1.3 | 0 | miRNATAP | -0.15 | 7.0E-5 | NA | |
| 59 | hsa-miR-34a-5p | CR2 | 1.9 | 0 | -1.53 | 0.0725 | MirTarget | -0.79 | 0 | NA | |
| 60 | hsa-miR-34a-5p | CREB5 | 1.9 | 0 | -2.28 | 0 | miRNATAP | -0.5 | 0 | NA | |
| 61 | hsa-miR-34a-5p | CRY2 | 1.9 | 0 | -1.68 | 0 | MirTarget | -0.17 | 0 | NA | |
| 62 | hsa-miR-34a-5p | CSF1R | 1.9 | 0 | -1.05 | 0.01797 | MirTarget; miRNATAP | -0.46 | 0 | NA | |
| 63 | hsa-miR-34a-5p | CTCFL | 1.9 | 0 | 0.39 | 0.13775 | MirTarget | -0.13 | 0.01043 | NA | |
| 64 | hsa-miR-34a-5p | CTDSP2 | 1.9 | 0 | -0.39 | 0.00969 | miRNATAP | -0.22 | 0 | NA | |
| 65 | hsa-miR-34a-5p | CXCL9 | 1.9 | 0 | 1.5 | 0.03653 | miRNAWalker2 validate | -0.48 | 0.00046 | NA | |
| 66 | hsa-miR-34a-5p | CYTH3 | 1.9 | 0 | -0.27 | 0.19343 | mirMAP | -0.3 | 0 | NA | |
| 67 | hsa-miR-34a-5p | DAAM1 | 1.9 | 0 | -0.94 | 0.00028 | MirTarget; miRNATAP | -0.31 | 0 | NA | |
| 68 | hsa-miR-34a-5p | DDAH2 | 1.9 | 0 | -0.59 | 0.01587 | miRNAWalker2 validate | -0.15 | 0.00124 | NA | |
| 69 | hsa-miR-34a-5p | DDX21 | 1.9 | 0 | -0.17 | 0.50092 | miRNAWalker2 validate | -0.18 | 0.00028 | NA | |
| 70 | hsa-miR-34a-5p | DDX24 | 1.9 | 0 | -0.7 | 0 | miRNAWalker2 validate | -0.18 | 0 | NA | |
| 71 | hsa-miR-34a-5p | DEGS1 | 1.9 | 0 | -0.46 | 0.09328 | miRNAWalker2 validate | -0.34 | 0 | NA | |
| 72 | hsa-miR-34a-5p | DIRAS1 | 1.9 | 0 | -3.19 | 0 | mirMAP | -0.65 | 0 | NA | |
| 73 | hsa-miR-34a-5p | DIXDC1 | 1.9 | 0 | -3.01 | 0 | MirTarget | -0.72 | 0 | NA | |
| 74 | hsa-miR-34a-5p | DLL1 | 1.9 | 0 | -0.9 | 0.01032 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.16 | 0.01552 | 22438124 | Delta tocotrienol suppresses Notch 1 pathway by upregulating miR 34a in nonsmall cell lung cancer cells |
| 75 | hsa-miR-34a-5p | DPYSL4 | 1.9 | 0 | -1.62 | 0.01387 | miRNATAP | -0.4 | 0.00131 | NA | |
| 76 | hsa-miR-34a-5p | DUSP8 | 1.9 | 0 | -2.17 | 0 | MirTarget | -0.35 | 0 | NA | |
| 77 | hsa-miR-34a-5p | EMP1 | 1.9 | 0 | -2.56 | 0 | miRNAWalker2 validate | -0.26 | 0.00013 | NA | |
| 78 | hsa-miR-34a-5p | EPB41L2 | 1.9 | 0 | -1.53 | 0 | miRNAWalker2 validate | -0.42 | 0 | NA | |
| 79 | hsa-miR-34a-5p | ERC1 | 1.9 | 0 | -1.1 | 0 | mirMAP; miRNATAP | -0.35 | 0 | NA | |
| 80 | hsa-miR-34a-5p | ESYT2 | 1.9 | 0 | -0.75 | 0 | miRNAWalker2 validate | -0.15 | 0 | NA | |
| 81 | hsa-miR-34a-5p | EVC | 1.9 | 0 | -1.68 | 3.0E-5 | mirMAP | -0.42 | 0 | NA | |
| 82 | hsa-miR-34a-5p | F2RL2 | 1.9 | 0 | -0.07 | 0.88286 | MirTarget; miRNATAP | -0.36 | 0.00013 | NA | |
| 83 | hsa-miR-34a-5p | FAIM2 | 1.9 | 0 | -5.19 | 0 | mirMAP | -0.83 | 0 | NA | |
| 84 | hsa-miR-34a-5p | FAM131B | 1.9 | 0 | -1.34 | 0.00082 | MirTarget | -0.46 | 0 | NA | |
| 85 | hsa-miR-34a-5p | FAM168A | 1.9 | 0 | -0.72 | 0.00481 | mirMAP | -0.36 | 0 | NA | |
| 86 | hsa-miR-34a-5p | FAM46A | 1.9 | 0 | -1.54 | 0 | miRNAWalker2 validate; miRNATAP | -0.15 | 0.00092 | NA | |
| 87 | hsa-miR-34a-5p | FAM78A | 1.9 | 0 | -0.18 | 0.57167 | mirMAP | -0.16 | 0.00572 | NA | |
| 88 | hsa-miR-34a-5p | FAT3 | 1.9 | 0 | -2.79 | 0 | miRNATAP | -0.24 | 0.03998 | NA | |
| 89 | hsa-miR-34a-5p | FAT4 | 1.9 | 0 | -2.57 | 0 | MirTarget | -0.55 | 0 | NA | |
| 90 | hsa-miR-34a-5p | FGD6 | 1.9 | 0 | 0.16 | 0.53702 | MirTarget; miRNATAP | -0.28 | 0 | NA | |
| 91 | hsa-miR-34a-5p | FIGN | 1.9 | 0 | -0.34 | 0.46881 | miRNAWalker2 validate | -0.28 | 0.00145 | NA | |
| 92 | hsa-miR-34a-5p | FMNL2 | 1.9 | 0 | -0.53 | 0.08935 | miRNATAP | -0.46 | 0 | 26103003 | MicroRNA 34a targets FMNL2 and E2F5 and suppresses the progression of colorectal cancer; FMNL2 and E2F5 were identified as direct targets of miR-34a; Reintroduction of FMNL2 or E2F5 without 3'UTR region reversed the inhibitory effects of miR-34a on cell proliferation and invasion; MiR-34a was down-regulated in CRC cells and inversely correlated with FMNL2 and E2F5 expressions; Our study suggests that miR-34a is an important tumor suppressor of CRC progression by targeting FMNL2 and E2F5 thus providing new insight into the molecular mechanisms underlying CRC progression and establishing a strong potential for the application of miR-34a as a novel therapeutic marker against CRC |
| 93 | hsa-miR-34a-5p | FOXJ2 | 1.9 | 0 | -0.62 | 0.00017 | MirTarget; miRNATAP | -0.17 | 0 | NA | |
| 94 | hsa-miR-34a-5p | FOXK1 | 1.9 | 0 | -0.29 | 0.13213 | mirMAP | -0.13 | 0.00029 | NA | |
| 95 | hsa-miR-34a-5p | FOXN2 | 1.9 | 0 | -0.2 | 0.26661 | miRNATAP | -0.11 | 0.00091 | NA | |
| 96 | hsa-miR-34a-5p | FOXN3 | 1.9 | 0 | -1.44 | 0 | miRNATAP | -0.29 | 0 | NA | |
| 97 | hsa-miR-34a-5p | FUT8 | 1.9 | 0 | -0.01 | 0.97182 | miRNATAP | -0.1 | 0.01165 | 27533464 | Furthermore using microRNA array we identified FUT8 as one of the miR-26a miR-34a and miR-146a-targeted genes |
| 98 | hsa-miR-34a-5p | GAB1 | 1.9 | 0 | -0.89 | 0 | MirTarget | -0.19 | 0 | NA | |
| 99 | hsa-miR-34a-5p | GAS1 | 1.9 | 0 | -2.19 | 0.00038 | miRNAWalker2 validate; miRNATAP | -0.93 | 0 | 24220341 | MiR 34a targets GAS1 to promote cell proliferation and inhibit apoptosis in papillary thyroid carcinoma via PI3K/Akt/Bad pathway; Both miR-34a and GAS1 are frequently down-regulated in various tumors; However it has been reported that while GAS1 is down-regulated in papillary thyroid carcinoma PTC miR-34a is up-regulated in this specific type of cancer although their potential roles in PTC tumorigenesis have not been examined to date; A computational search revealed that miR-34a putatively binds to the 3'-UTR of GAS1 gene; In the present study we confirmed previous findings that miR-34a is up-regulated and GAS1 down-regulated in PTC tissues; Further studies indicated that GAS1 is directly targeted by miR-34a; Silencing of GAS1 had similar growth-promoting effects as overexpression of miR-34a; Taken together our results demonstrate that miR-34a regulates GAS1 expression to promote proliferation and suppress apoptosis in PTC cells via PI3K/Akt/Bad pathway |
| 100 | hsa-miR-34a-5p | GBP5 | 1.9 | 0 | 0.91 | 0.15545 | MirTarget | -0.38 | 0.00174 | NA | |
| 101 | hsa-miR-34a-5p | GDPD5 | 1.9 | 0 | -0.63 | 0.02939 | mirMAP | -0.21 | 0.0001 | NA | |
| 102 | hsa-miR-34a-5p | GEMIN5 | 1.9 | 0 | -0.2 | 0.12024 | miRNAWalker2 validate | -0.12 | 0 | NA | |
| 103 | hsa-miR-34a-5p | GFRA1 | 1.9 | 0 | -5 | 0 | miRNATAP | -0.47 | 0.00012 | NA | |
| 104 | hsa-miR-34a-5p | GLCE | 1.9 | 0 | 0.26 | 0.17205 | MirTarget; miRNATAP | -0.1 | 0.00414 | NA | |
| 105 | hsa-miR-34a-5p | GLIS2 | 1.9 | 0 | -0.61 | 0.05279 | MirTarget | -0.4 | 0 | NA | |
| 106 | hsa-miR-34a-5p | GNAO1 | 1.9 | 0 | -3.6 | 0 | mirMAP | -0.91 | 0 | NA | |
| 107 | hsa-miR-34a-5p | GPC6 | 1.9 | 0 | -2.71 | 0 | MirTarget | -0.76 | 0 | NA | |
| 108 | hsa-miR-34a-5p | GPR156 | 1.9 | 0 | -1.26 | 0.01362 | MirTarget | -0.83 | 0 | NA | |
| 109 | hsa-miR-34a-5p | GREM2 | 1.9 | 0 | -4.99 | 0 | MirTarget; miRNATAP | -0.44 | 0.00048 | NA | |
| 110 | hsa-miR-34a-5p | GRID1 | 1.9 | 0 | -0.62 | 0.16867 | miRNATAP | -0.18 | 0.03862 | NA | |
| 111 | hsa-miR-34a-5p | GYG1 | 1.9 | 0 | -0.71 | 0 | miRNAWalker2 validate | -0.14 | 0 | NA | |
| 112 | hsa-miR-34a-5p | HAPLN4 | 1.9 | 0 | 0.13 | 0.77621 | mirMAP | -0.21 | 0.01431 | NA | |
| 113 | hsa-miR-34a-5p | HIPK2 | 1.9 | 0 | -0.57 | 0.01764 | mirMAP | -0.22 | 0 | NA | |
| 114 | hsa-miR-34a-5p | HMGA2 | 1.9 | 0 | 3.21 | 0.00037 | miRNAWalker2 validate | -0.57 | 0.00093 | 18803879 | miR-34 targets Notch HMGA2 and Bcl-2 genes involved in the self-renewal and survival of cancer stem cells; Human gastric cancer Kato III cells with miR-34 restoration reduced the expression of target genes Bcl-2 Notch and HMGA2; The mechanism of miR-34-mediated suppression of self-renewal appears to be related to the direct modulation of downstream targets Bcl-2 Notch and HMGA2 indicating that miR-34 may be involved in gastric cancer stem cell self-renewal/differentiation decision-making |
| 115 | hsa-miR-34a-5p | HPSE | 1.9 | 0 | 0.67 | 0.15614 | MirTarget | -0.42 | 0 | NA | |
| 116 | hsa-miR-34a-5p | IGF2BP3 | 1.9 | 0 | 2.63 | 0.00021 | miRNAWalker2 validate | -0.36 | 0.0089 | NA | |
| 117 | hsa-miR-34a-5p | IGFBP5 | 1.9 | 0 | -2.81 | 0 | mirMAP | -0.66 | 0 | NA | |
| 118 | hsa-miR-34a-5p | IL6R | 1.9 | 0 | -1.87 | 0 | MirTarget | -0.29 | 0.00017 | NA | |
| 119 | hsa-miR-34a-5p | INHBB | 1.9 | 0 | -1.64 | 0 | miRNATAP | -0.24 | 0.00018 | NA | |
| 120 | hsa-miR-34a-5p | ITPKB | 1.9 | 0 | -1.7 | 0 | mirMAP | -0.25 | 0 | NA | |
| 121 | hsa-miR-34a-5p | ITPR2 | 1.9 | 0 | -0.18 | 0.43611 | MirTarget | -0.2 | 0 | NA | |
| 122 | hsa-miR-34a-5p | ITSN1 | 1.9 | 0 | -0.61 | 9.0E-5 | mirMAP | -0.17 | 0 | NA | |
| 123 | hsa-miR-34a-5p | JAKMIP1 | 1.9 | 0 | 0.37 | 0.50423 | MirTarget; miRNATAP | -0.28 | 0.00901 | NA | |
| 124 | hsa-miR-34a-5p | JMJD1C | 1.9 | 0 | -0.84 | 0 | miRNATAP | -0.16 | 0 | NA | |
| 125 | hsa-miR-34a-5p | KCNAB2 | 1.9 | 0 | -0.72 | 0.01568 | MirTarget; mirMAP | -0.31 | 0 | NA | |
| 126 | hsa-miR-34a-5p | KCNK3 | 1.9 | 0 | -3.63 | 0 | MirTarget | -0.57 | 0 | NA | |
| 127 | hsa-miR-34a-5p | KCNQ4 | 1.9 | 0 | -2.64 | 0 | mirMAP | -0.69 | 0 | NA | |
| 128 | hsa-miR-34a-5p | KIAA1462 | 1.9 | 0 | -1.72 | 0 | MirTarget | -0.43 | 0 | NA | |
| 129 | hsa-miR-34a-5p | KIAA1644 | 1.9 | 0 | -4.4 | 0 | MirTarget | -0.99 | 0 | NA | |
| 130 | hsa-miR-34a-5p | KIF2A | 1.9 | 0 | -0.22 | 0.23146 | miRNAWalker2 validate | -0.17 | 0 | NA | |
| 131 | hsa-miR-34a-5p | KIF5B | 1.9 | 0 | -0.64 | 0 | miRNAWalker2 validate | -0.12 | 0 | NA | |
| 132 | hsa-miR-34a-5p | KIT | 1.9 | 0 | -2.52 | 0 | MirTarget | -0.31 | 0.00151 | NA | |
| 133 | hsa-miR-34a-5p | KITLG | 1.9 | 0 | -1.58 | 1.0E-5 | MirTarget | -0.47 | 0 | NA | |
| 134 | hsa-miR-34a-5p | KLC1 | 1.9 | 0 | -0.61 | 0 | miRNAWalker2 validate | -0.12 | 0 | NA | |
| 135 | hsa-miR-34a-5p | KLF13 | 1.9 | 0 | -1.16 | 1.0E-5 | mirMAP | -0.35 | 0 | NA | |
| 136 | hsa-miR-34a-5p | KLF4 | 1.9 | 0 | -2.67 | 0 | MirTarget; miRNATAP | -0.15 | 0.02259 | NA | |
| 137 | hsa-miR-34a-5p | KLF7 | 1.9 | 0 | -0.4 | 0.17032 | miRNATAP | -0.38 | 0 | NA | |
| 138 | hsa-miR-34a-5p | KY | 1.9 | 0 | -3.92 | 0 | MirTarget | -0.78 | 0 | NA | |
| 139 | hsa-miR-34a-5p | LDHA | 1.9 | 0 | 0.41 | 0.08988 | miRNAWalker2 validate; MirTarget; miRNATAP | -0.19 | 2.0E-5 | 26902416; 25333573; 27186405 | The miR 34a LDHA axis regulates glucose metabolism and tumor growth in breast cancer; We also performed luciferase reporter assays and found that LDHA was a direct target of miR-34a; Repression of LDHA by miR-34a suppressed glycolysis and cell proliferation in breast cancer cells in vitro; Our findings provide clues regarding the role of miR-34a as a tumor suppressor in breast cancer through the inhibition of LDHA both in vitro and in vivo; Targeting LDHA through miR-34a could be a potential therapeutic strategy in breast cancer;Inhibition of lactate dehydrogenase A by microRNA 34a resensitizes colon cancer cells to 5 fluorouracil; Furthermore LDHA was shown to be a direct target of miR-34a; Overexpression of miR-34a reduced the expression of LDHA probably through binding to the 3' untranslated region leading to the re-sensitization of 5-FU-resistant cancer cells to 5-FU; In conclusion the current study showed that miR-34a is involved in sensitivity to 5-FU in part through its effects on LDHA expression;HPV E6/p53 mediated down regulation of miR 34a inhibits Warburg effect through targeting LDHA in cervical cancer; Subsequently lactate dehydrogenase A LDHA which catalyzes the last key step in glycolysis was identified as a direct target of miR-34a; Silencing of LDHA or introduction of miR-34a significantly attenuated colony formation ability and invasive capacity of SiHa and HeLa cells and these effects were fully compromised by reintroduction of LDHA |
| 140 | hsa-miR-34a-5p | LHX2 | 1.9 | 0 | 2.07 | 0.00089 | miRNATAP | -0.26 | 0.02741 | NA | |
| 141 | hsa-miR-34a-5p | LOXL3 | 1.9 | 0 | -0.97 | 0.00081 | MirTarget; miRNATAP | -0.4 | 0 | NA | |
| 142 | hsa-miR-34a-5p | LRCH1 | 1.9 | 0 | -1.09 | 0 | MirTarget | -0.24 | 0 | NA | |
| 143 | hsa-miR-34a-5p | LRRC40 | 1.9 | 0 | -0.05 | 0.75514 | miRNAWalker2 validate; MirTarget | -0.11 | 0.00012 | NA | |
| 144 | hsa-miR-34a-5p | LRRC7 | 1.9 | 0 | -3.92 | 0 | MirTarget | -0.58 | 0 | NA | |
| 145 | hsa-miR-34a-5p | MAP1A | 1.9 | 0 | -2.82 | 0 | MirTarget; miRNATAP | -0.63 | 0 | NA | |
| 146 | hsa-miR-34a-5p | MAP1B | 1.9 | 0 | -3.18 | 0 | miRNAWalker2 validate | -0.79 | 0 | NA | |
| 147 | hsa-miR-34a-5p | MAP3K14 | 1.9 | 0 | -0.93 | 1.0E-5 | MirTarget | -0.17 | 4.0E-5 | NA | |
| 148 | hsa-miR-34a-5p | MAP4 | 1.9 | 0 | -0.68 | 0 | miRNAWalker2 validate | -0.15 | 0 | NA | |
| 149 | hsa-miR-34a-5p | MAP4K4 | 1.9 | 0 | 0.13 | 0.52281 | MirTarget | -0.26 | 0 | NA | |
| 150 | hsa-miR-34a-5p | MAPK1 | 1.9 | 0 | -0.3 | 0.02025 | mirMAP | -0.11 | 0 | NA |
| Num | GO | Overlap | Size | P Value | Adj. P Value |
|---|---|---|---|---|---|
| 1 | NEUROGENESIS | 65 | 1402 | 8.837e-16 | 4.112e-12 |
| 2 | REGULATION OF CELL DIFFERENTIATION | 65 | 1492 | 1.717e-14 | 3.994e-11 |
| 3 | HEAD DEVELOPMENT | 41 | 709 | 3.667e-13 | 5.688e-10 |
| 4 | INTRACELLULAR SIGNAL TRANSDUCTION | 64 | 1572 | 6.232e-13 | 7.249e-10 |
| 5 | REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT | 66 | 1672 | 1.021e-12 | 7.919e-10 |
| 6 | CELL DEVELOPMENT | 60 | 1426 | 9.65e-13 | 7.919e-10 |
| 7 | CENTRAL NERVOUS SYSTEM DEVELOPMENT | 45 | 872 | 1.237e-12 | 8.222e-10 |
| 8 | POSITIVE REGULATION OF CELL COMMUNICATION | 62 | 1532 | 2.013e-12 | 1.171e-09 |
| 9 | REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS | 48 | 1021 | 5.716e-12 | 2.955e-09 |
| 10 | NEURON DIFFERENTIATION | 43 | 874 | 1.96e-11 | 9.121e-09 |
| 11 | MOVEMENT OF CELL OR SUBCELLULAR COMPONENT | 53 | 1275 | 4.091e-11 | 1.731e-08 |
| 12 | POSITIVE REGULATION OF RESPONSE TO STIMULUS | 68 | 1929 | 7.193e-11 | 2.789e-08 |
| 13 | POSITIVE REGULATION OF DEVELOPMENTAL PROCESS | 49 | 1142 | 8.44e-11 | 3.021e-08 |
| 14 | REGULATION OF PHOSPHORUS METABOLIC PROCESS | 60 | 1618 | 1.719e-10 | 5.713e-08 |
| 15 | CELL PROJECTION ORGANIZATION | 42 | 902 | 1.907e-10 | 5.915e-08 |
| 16 | REGULATION OF CELL DEVELOPMENT | 40 | 836 | 2.437e-10 | 7.088e-08 |
| 17 | REGULATION OF CELLULAR COMPONENT MOVEMENT | 38 | 771 | 3.107e-10 | 8.504e-08 |
| 18 | TISSUE DEVELOPMENT | 57 | 1518 | 3.386e-10 | 8.752e-08 |
| 19 | CELLULAR COMPONENT MORPHOGENESIS | 41 | 900 | 6.165e-10 | 1.51e-07 |
| 20 | REGULATION OF PROTEIN MODIFICATION PROCESS | 60 | 1710 | 1.476e-09 | 3.433e-07 |
| 21 | POSITIVE REGULATION OF GENE EXPRESSION | 59 | 1733 | 6.388e-09 | 1.415e-06 |
| 22 | NEURON PROJECTION DEVELOPMENT | 29 | 545 | 8.47e-09 | 1.792e-06 |
| 23 | NEURON DEVELOPMENT | 33 | 687 | 9.396e-09 | 1.879e-06 |
| 24 | FOREBRAIN DEVELOPMENT | 23 | 357 | 9.692e-09 | 1.879e-06 |
| 25 | REGULATION OF CELL MORPHOGENESIS | 29 | 552 | 1.124e-08 | 2.091e-06 |
| 26 | REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 56 | 1656 | 2.125e-08 | 3.699e-06 |
| 27 | POSITIVE REGULATION OF CELL DIFFERENTIATION | 36 | 823 | 2.146e-08 | 3.699e-06 |
| 28 | POSITIVE REGULATION OF BIOSYNTHETIC PROCESS | 59 | 1805 | 2.787e-08 | 4.631e-06 |
| 29 | LOCOMOTION | 43 | 1114 | 3.148e-08 | 5.051e-06 |
| 30 | POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 49 | 1395 | 5.959e-08 | 9.242e-06 |
| 31 | CELLULAR RESPONSE TO ORGANIC SUBSTANCE | 59 | 1848 | 6.401e-08 | 9.608e-06 |
| 32 | MUSCLE STRUCTURE DEVELOPMENT | 24 | 432 | 7.764e-08 | 1.129e-05 |
| 33 | NEURON PROJECTION MORPHOGENESIS | 23 | 402 | 8.619e-08 | 1.215e-05 |
| 34 | POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 36 | 876 | 1.023e-07 | 1.4e-05 |
| 35 | POSITIVE REGULATION OF SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION | 8 | 39 | 1.233e-07 | 1.64e-05 |
| 36 | IMMUNE SYSTEM DEVELOPMENT | 28 | 582 | 1.288e-07 | 1.664e-05 |
| 37 | CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 26 | 513 | 1.352e-07 | 1.689e-05 |
| 38 | NEURON PROJECTION GUIDANCE | 16 | 205 | 1.38e-07 | 1.689e-05 |
| 39 | EMBRYO DEVELOPMENT | 36 | 894 | 1.683e-07 | 1.962e-05 |
| 40 | REGULATION OF NEURON DIFFERENTIATION | 27 | 554 | 1.687e-07 | 1.962e-05 |
| 41 | CELL PART MORPHOGENESIS | 29 | 633 | 2.128e-07 | 2.415e-05 |
| 42 | PROTEIN PHOSPHORYLATION | 37 | 944 | 2.184e-07 | 2.42e-05 |
| 43 | POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 39 | 1036 | 2.808e-07 | 2.969e-05 |
| 44 | POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 39 | 1036 | 2.808e-07 | 2.969e-05 |
| 45 | CELL MORPHOGENESIS INVOLVED IN NEURON DIFFERENTIATION | 21 | 368 | 3.327e-07 | 3.44e-05 |
| 46 | EMBRYONIC MORPHOGENESIS | 26 | 539 | 3.511e-07 | 3.552e-05 |
| 47 | GROWTH | 22 | 410 | 4.955e-07 | 4.905e-05 |
| 48 | TELENCEPHALON DEVELOPMENT | 16 | 228 | 5.843e-07 | 5.664e-05 |
| 49 | ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS | 36 | 957 | 8.552e-07 | 7.97e-05 |
| 50 | SENSORY ORGAN DEVELOPMENT | 24 | 493 | 8.564e-07 | 7.97e-05 |
| 51 | TISSUE MORPHOGENESIS | 25 | 533 | 9.922e-07 | 9.053e-05 |
| 52 | TAXIS | 23 | 464 | 1.072e-06 | 9.592e-05 |
| 53 | POSITIVE REGULATION OF CELL DEVELOPMENT | 23 | 472 | 1.434e-06 | 0.0001259 |
| 54 | REGULATION OF HYDROLASE ACTIVITY | 44 | 1327 | 1.471e-06 | 0.0001267 |
| 55 | POSITIVE REGULATION OF NEURON DIFFERENTIATION | 18 | 306 | 1.52e-06 | 0.0001286 |
| 56 | REGULATION OF ACTIN FILAMENT BASED PROCESS | 18 | 312 | 2.003e-06 | 0.0001664 |
| 57 | REGULATION OF HOMEOSTATIC PROCESS | 22 | 447 | 2.076e-06 | 0.0001695 |
| 58 | REGULATION OF NERVOUS SYSTEM DEVELOPMENT | 30 | 750 | 2.206e-06 | 0.000177 |
| 59 | POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 36 | 1004 | 2.582e-06 | 0.0002036 |
| 60 | CYTOSKELETON ORGANIZATION | 32 | 838 | 2.656e-06 | 0.000206 |
| 61 | CELLULAR RESPONSE TO ENDOGENOUS STIMULUS | 36 | 1008 | 2.826e-06 | 0.0002155 |
| 62 | POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 39 | 1152 | 3.806e-06 | 0.0002856 |
| 63 | HEART DEVELOPMENT | 22 | 466 | 4.066e-06 | 0.0003003 |
| 64 | REGULATION OF MAPK CASCADE | 27 | 660 | 4.825e-06 | 0.0003508 |
| 65 | REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 18 | 337 | 5.879e-06 | 0.0004089 |
| 66 | CARDIOVASCULAR SYSTEM DEVELOPMENT | 30 | 788 | 5.888e-06 | 0.0004089 |
| 67 | CIRCULATORY SYSTEM DEVELOPMENT | 30 | 788 | 5.888e-06 | 0.0004089 |
| 68 | MUSCLE TISSUE DEVELOPMENT | 16 | 275 | 6.698e-06 | 0.0004583 |
| 69 | PHOSPHORYLATION | 40 | 1228 | 7.113e-06 | 0.0004796 |
| 70 | REGULATION OF CELL PROJECTION ORGANIZATION | 24 | 558 | 7.221e-06 | 0.00048 |
| 71 | MUSCLE ORGAN DEVELOPMENT | 16 | 277 | 7.339e-06 | 0.000481 |
| 72 | ACTIN FILAMENT BASED PROCESS | 21 | 450 | 8.062e-06 | 0.0005162 |
| 73 | NEGATIVE REGULATION OF DEVELOPMENTAL PROCESS | 30 | 801 | 8.099e-06 | 0.0005162 |
| 74 | NEURON MIGRATION | 10 | 110 | 8.269e-06 | 0.00052 |
| 75 | CELL GROWTH | 11 | 135 | 8.452e-06 | 0.0005243 |
| 76 | REGULATION OF TRANSPORT | 52 | 1804 | 8.992e-06 | 0.0005505 |
| 77 | NEGATIVE REGULATION OF CELL DIFFERENTIATION | 25 | 609 | 1.034e-05 | 0.0006247 |
| 78 | NEGATIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 34 | 983 | 1.073e-05 | 0.00064 |
| 79 | RESPONSE TO EXTERNAL STIMULUS | 52 | 1821 | 1.167e-05 | 0.0006818 |
| 80 | REGULATION OF MUSCLE SYSTEM PROCESS | 13 | 195 | 1.172e-05 | 0.0006818 |
| 81 | EPITHELIUM DEVELOPMENT | 33 | 945 | 1.2e-05 | 0.0006895 |
| 82 | LEUKOCYTE DIFFERENTIATION | 16 | 292 | 1.418e-05 | 0.0007949 |
| 83 | RESPONSE TO ENDOGENOUS STIMULUS | 44 | 1450 | 1.412e-05 | 0.0007949 |
| 84 | NEGATIVE REGULATION OF RESPONSE TO STIMULUS | 42 | 1360 | 1.496e-05 | 0.0008285 |
| 85 | REGULATION OF SYSTEM PROCESS | 22 | 507 | 1.528e-05 | 0.0008366 |
| 86 | POSITIVE REGULATION OF MOLECULAR FUNCTION | 51 | 1791 | 1.551e-05 | 0.0008391 |
| 87 | POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 37 | 1135 | 1.592e-05 | 0.0008513 |
| 88 | RHYTHMIC PROCESS | 16 | 298 | 1.822e-05 | 0.0009633 |
| 89 | CELL PROLIFERATION | 26 | 672 | 1.918e-05 | 0.0009916 |
| 90 | DEVELOPMENTAL GROWTH | 17 | 333 | 1.915e-05 | 0.0009916 |
| 91 | RESPONSE TO CYTOKINE | 27 | 714 | 1.978e-05 | 0.001 |
| 92 | SIGNAL TRANSDUCTION BY PROTEIN PHOSPHORYLATION | 19 | 404 | 1.964e-05 | 0.001 |
| 93 | CELLULAR RESPONSE TO OXYGEN CONTAINING COMPOUND | 29 | 799 | 2.067e-05 | 0.001023 |
| 94 | ORGAN MORPHOGENESIS | 30 | 841 | 2.053e-05 | 0.001023 |
| 95 | POSITIVE REGULATION OF CELL PROJECTION ORGANIZATION | 16 | 303 | 2.233e-05 | 0.001094 |
| 96 | REGULATION OF METANEPHROS DEVELOPMENT | 5 | 23 | 2.318e-05 | 0.001123 |
| 97 | REGULATION OF CALCIUM ION TRANSPORT | 13 | 209 | 2.448e-05 | 0.001174 |
| 98 | REGULATION OF CYTOKINE PRODUCTION | 23 | 563 | 2.538e-05 | 0.001194 |
| 99 | LATERAL VENTRICLE DEVELOPMENT | 4 | 12 | 2.54e-05 | 0.001194 |
| 100 | PHOSPHATE CONTAINING COMPOUND METABOLIC PROCESS | 54 | 1977 | 2.687e-05 | 0.00125 |
| 101 | REGULATION OF MEMBRANE POTENTIAL | 17 | 343 | 2.79e-05 | 0.001273 |
| 102 | CELLULAR RESPONSE TO CYTOKINE STIMULUS | 24 | 606 | 2.787e-05 | 0.001273 |
| 103 | POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS | 44 | 1492 | 2.824e-05 | 0.001276 |
| 104 | REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 50 | 1784 | 2.893e-05 | 0.001294 |
| 105 | SKELETAL SYSTEM DEVELOPMENT | 20 | 455 | 3.121e-05 | 0.001383 |
| 106 | NEGATIVE REGULATION OF PROTEIN METABOLIC PROCESS | 35 | 1087 | 3.538e-05 | 0.001539 |
| 107 | REGULATION OF ORGANELLE ORGANIZATION | 37 | 1178 | 3.54e-05 | 0.001539 |
| 108 | NEGATIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 27 | 740 | 3.677e-05 | 0.001584 |
| 109 | REGULATION OF CYTOSKELETON ORGANIZATION | 21 | 502 | 4.076e-05 | 0.00174 |
| 110 | VENTRICULAR SYSTEM DEVELOPMENT | 5 | 26 | 4.361e-05 | 0.001828 |
| 111 | STEM CELL DIFFERENTIATION | 12 | 190 | 4.322e-05 | 0.001828 |
| 112 | CELL MOTILITY | 29 | 835 | 4.589e-05 | 0.001873 |
| 113 | LOCALIZATION OF CELL | 29 | 835 | 4.589e-05 | 0.001873 |
| 114 | NEGATIVE REGULATION OF CELL COMMUNICATION | 37 | 1192 | 4.54e-05 | 0.001873 |
| 115 | POSITIVE REGULATION OF MUSCLE CELL DIFFERENTIATION | 8 | 84 | 4.778e-05 | 0.001933 |
| 116 | REGULATION OF METAL ION TRANSPORT | 16 | 325 | 5.194e-05 | 0.002083 |
| 117 | REGULATION OF CARDIAC MUSCLE CELL CONTRACTION | 5 | 27 | 5.285e-05 | 0.002102 |
| 118 | EYE DEVELOPMENT | 16 | 326 | 5.387e-05 | 0.00211 |
| 119 | REGULATION OF GTPASE ACTIVITY | 25 | 673 | 5.396e-05 | 0.00211 |
| 120 | TUBE DEVELOPMENT | 22 | 552 | 5.502e-05 | 0.002133 |
| 121 | EAR DEVELOPMENT | 12 | 195 | 5.563e-05 | 0.002139 |
| 122 | MORPHOGENESIS OF AN EPITHELIUM | 18 | 400 | 5.757e-05 | 0.002146 |
| 123 | POSITIVE REGULATION OF NERVOUS SYSTEM DEVELOPMENT | 19 | 437 | 5.698e-05 | 0.002146 |
| 124 | RESPONSE TO GROWTH FACTOR | 20 | 475 | 5.685e-05 | 0.002146 |
| 125 | CELL FATE COMMITMENT | 13 | 227 | 5.766e-05 | 0.002146 |
| 126 | REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE SIGNALING | 10 | 138 | 5.956e-05 | 0.002199 |
| 127 | NEGATIVE REGULATION OF GENE EXPRESSION | 43 | 1493 | 6.084e-05 | 0.002229 |
| 128 | MYELOID CELL HOMEOSTASIS | 8 | 88 | 6.678e-05 | 0.002379 |
| 129 | NEGATIVE REGULATION OF LOCOMOTION | 14 | 263 | 6.652e-05 | 0.002379 |
| 130 | OVULATION CYCLE | 9 | 113 | 6.698e-05 | 0.002379 |
| 131 | OVULATION CYCLE PROCESS | 8 | 88 | 6.678e-05 | 0.002379 |
| 132 | UROGENITAL SYSTEM DEVELOPMENT | 15 | 299 | 7.194e-05 | 0.002536 |
| 133 | MODULATION OF SYNAPTIC TRANSMISSION | 15 | 301 | 7.752e-05 | 0.002712 |
| 134 | POSITIVE REGULATION OF HYDROLASE ACTIVITY | 30 | 905 | 7.873e-05 | 0.002713 |
| 135 | ENZYME LINKED RECEPTOR PROTEIN SIGNALING PATHWAY | 25 | 689 | 7.847e-05 | 0.002713 |
| 136 | FEMALE SEX DIFFERENTIATION | 9 | 116 | 8.214e-05 | 0.00281 |
| 137 | POSITIVE REGULATION OF CATALYTIC ACTIVITY | 43 | 1518 | 8.869e-05 | 0.003012 |
| 138 | NEURON MATURATION | 5 | 30 | 8.98e-05 | 0.003028 |
| 139 | NEGATIVE REGULATION OF CELL DEATH | 29 | 872 | 9.829e-05 | 0.00329 |
| 140 | RESPONSE TO OXYGEN CONTAINING COMPOUND | 40 | 1381 | 9.989e-05 | 0.00332 |
| 141 | LYMPHOCYTE DIFFERENTIATION | 12 | 209 | 0.000108 | 0.003565 |
| 142 | IMMUNE SYSTEM PROCESS | 52 | 1984 | 0.000113 | 0.003702 |
| 143 | MYELIN ASSEMBLY | 4 | 17 | 0.0001149 | 0.003738 |
| 144 | CARDIOCYTE DIFFERENTIATION | 8 | 96 | 0.0001238 | 0.003973 |
| 145 | REGULATION OF ACTIN FILAMENT BASED MOVEMENT | 5 | 32 | 0.0001237 | 0.003973 |
| 146 | REGULATION OF CELL PROLIFERATION | 42 | 1496 | 0.0001313 | 0.004184 |
| 147 | REGULATION OF MUSCLE CELL DIFFERENTIATION | 10 | 152 | 0.0001336 | 0.004228 |
| 148 | PALLIUM DEVELOPMENT | 10 | 153 | 0.000141 | 0.004432 |
| 149 | CELL CYCLE ARREST | 10 | 154 | 0.0001487 | 0.004645 |
| 150 | TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 25 | 724 | 0.0001697 | 0.005264 |
| 151 | POSITIVE REGULATION OF CELL PROLIFERATION | 27 | 814 | 0.0001792 | 0.005521 |
| 152 | NEGATIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 24 | 684 | 0.0001808 | 0.005534 |
| 153 | REGULATION OF HEART CONTRACTION | 12 | 221 | 0.0001823 | 0.005544 |
| 154 | REGULATION OF CELLULAR LOCALIZATION | 37 | 1277 | 0.0001844 | 0.005549 |
| 155 | MYELOID CELL DIFFERENTIATION | 11 | 189 | 0.0001848 | 0.005549 |
| 156 | REGULATION OF CELL DEATH | 41 | 1472 | 0.000188 | 0.005572 |
| 157 | NEGATIVE REGULATION OF CELL PROLIFERATION | 23 | 643 | 0.0001869 | 0.005572 |
| 158 | MESENCHYME DEVELOPMENT | 11 | 190 | 0.0001936 | 0.0057 |
| 159 | REGULATION OF CYTOPLASMIC TRANSPORT | 19 | 481 | 0.0001983 | 0.005803 |
| 160 | REGULATION OF KINASE ACTIVITY | 26 | 776 | 0.0002021 | 0.005812 |
| 161 | CELL DEATH | 31 | 1001 | 0.0002024 | 0.005812 |
| 162 | REGULATION OF CALCIUM ION IMPORT | 8 | 103 | 0.0002022 | 0.005812 |
| 163 | RETINA DEVELOPMENT IN CAMERA TYPE EYE | 9 | 131 | 0.0002081 | 0.005941 |
| 164 | VESICLE MEDIATED TRANSPORT | 36 | 1239 | 0.0002145 | 0.006087 |
| 165 | MAINTENANCE OF CELL NUMBER | 9 | 132 | 0.0002204 | 0.006215 |
| 166 | REGULATION OF HISTONE METHYLATION | 6 | 56 | 0.0002236 | 0.006244 |
| 167 | BONE GROWTH | 4 | 20 | 0.0002254 | 0.006244 |
| 168 | POSITIVE REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 10 | 162 | 0.0002248 | 0.006244 |
| 169 | CELL ACTIVATION | 21 | 568 | 0.0002284 | 0.006282 |
| 170 | CEREBRAL CORTEX DEVELOPMENT | 8 | 105 | 0.0002309 | 0.006282 |
| 171 | REGULATION OF NEURON PROJECTION DEVELOPMENT | 17 | 408 | 0.0002307 | 0.006282 |
| 172 | MESENCHYMAL CELL DIFFERENTIATION | 9 | 134 | 0.0002467 | 0.006673 |
| 173 | AXON EXTENSION | 5 | 37 | 0.0002514 | 0.006761 |
| 174 | GLIAL CELL DIFFERENTIATION | 9 | 136 | 0.0002755 | 0.007367 |
| 175 | POSITIVE REGULATION OF NEURON PROJECTION DEVELOPMENT | 12 | 232 | 0.000285 | 0.007579 |
| 176 | REGULATION OF ION HOMEOSTASIS | 11 | 201 | 0.0003146 | 0.008317 |
| 177 | POSITIVE REGULATION OF LOCOMOTION | 17 | 420 | 0.0003229 | 0.008488 |
| 178 | CEREBELLAR CORTEX FORMATION | 4 | 22 | 0.0003322 | 0.008634 |
| 179 | CELLULAR RESPONSE TO INTERLEUKIN 6 | 4 | 22 | 0.0003322 | 0.008634 |
| 180 | CARDIAC MUSCLE TISSUE DEVELOPMENT | 9 | 140 | 0.0003416 | 0.008807 |
| 181 | BIOLOGICAL ADHESION | 31 | 1032 | 0.0003426 | 0.008807 |
| 182 | MUSCLE CELL DIFFERENTIATION | 12 | 237 | 0.000346 | 0.008845 |
| 183 | REGULATION OF CELL ADHESION | 22 | 629 | 0.0003503 | 0.008906 |
| 184 | CARDIAC SEPTUM DEVELOPMENT | 7 | 85 | 0.0003528 | 0.008921 |
| 185 | OVARIAN FOLLICLE DEVELOPMENT | 6 | 61 | 0.0003584 | 0.009006 |
| 186 | ESTABLISHMENT OR MAINTENANCE OF CELL POLARITY | 9 | 141 | 0.00036 | 0.009006 |
| 187 | STRIATED MUSCLE CELL DIFFERENTIATION | 10 | 173 | 0.0003806 | 0.009469 |
| 188 | REGULATION OF SMOOTHENED SIGNALING PATHWAY | 6 | 62 | 0.0003917 | 0.009696 |
| 189 | PROTEIN TARGETING TO PLASMA MEMBRANE | 4 | 23 | 0.0003972 | 0.009779 |
| 190 | REGULATION OF EMBRYONIC DEVELOPMENT | 8 | 114 | 0.0004042 | 0.009899 |
| Num | GO | Overlap | Size | P Value | Adj. P Value |
|---|---|---|---|---|---|
| 1 | ENZYME BINDING | 55 | 1737 | 2.568e-07 | 0.0002386 |
| 2 | TRANSCRIPTIONAL ACTIVATOR ACTIVITY RNA POLYMERASE II CORE PROMOTER PROXIMAL REGION SEQUENCE SPECIFIC BINDING | 16 | 226 | 5.192e-07 | 0.0002412 |
| 3 | TRANSCRIPTION FACTOR ACTIVITY RNA POLYMERASE II CORE PROMOTER PROXIMAL REGION SEQUENCE SPECIFIC BINDING | 19 | 328 | 9.764e-07 | 0.0003024 |
| 4 | REGULATORY REGION NUCLEIC ACID BINDING | 31 | 818 | 4.479e-06 | 0.0009377 |
| 5 | RNA POLYMERASE II TRANSCRIPTION FACTOR ACTIVITY SEQUENCE SPECIFIC DNA BINDING | 26 | 629 | 6.056e-06 | 0.0009377 |
| 6 | SEQUENCE SPECIFIC DNA BINDING | 36 | 1037 | 5.338e-06 | 0.0009377 |
| 7 | TRANSCRIPTIONAL ACTIVATOR ACTIVITY RNA POLYMERASE II TRANSCRIPTION REGULATORY REGION SEQUENCE SPECIFIC BINDING | 17 | 315 | 9.337e-06 | 0.001124 |
| 8 | NUCLEIC ACID BINDING TRANSCRIPTION FACTOR ACTIVITY | 39 | 1199 | 9.676e-06 | 0.001124 |
| 9 | CYTOSKELETAL PROTEIN BINDING | 30 | 819 | 1.242e-05 | 0.001282 |
| 10 | RAS GUANYL NUCLEOTIDE EXCHANGE FACTOR ACTIVITY | 14 | 228 | 1.383e-05 | 0.001285 |
| 11 | ACTIN BINDING | 18 | 393 | 4.586e-05 | 0.003873 |
| 12 | DOUBLE STRANDED DNA BINDING | 27 | 764 | 6.321e-05 | 0.004517 |
| 13 | GTPASE BINDING | 15 | 295 | 6.182e-05 | 0.004517 |
| 14 | TRANSCRIPTION FACTOR BINDING | 21 | 524 | 7.516e-05 | 0.004988 |
| 15 | GUANYL NUCLEOTIDE EXCHANGE FACTOR ACTIVITY | 15 | 303 | 8.348e-05 | 0.00517 |
| 16 | SMAD BINDING | 7 | 72 | 0.0001249 | 0.006531 |
| 17 | CORE PROMOTER BINDING | 10 | 152 | 0.0001336 | 0.006531 |
| 18 | KINASE ACTIVITY | 28 | 842 | 0.0001301 | 0.006531 |
| 19 | CALMODULIN BINDING | 11 | 179 | 0.0001146 | 0.006531 |
| 20 | PROTEIN KINASE ACTIVITY | 23 | 640 | 0.0001747 | 0.008113 |
| 21 | PHOSPHATASE BINDING | 10 | 162 | 0.0002248 | 0.009945 |
| Num | GO | Overlap | Size | P Value | Adj. P Value |
|---|---|---|---|---|---|
| 1 | CELL JUNCTION | 42 | 1151 | 2.163e-07 | 0.0001263 |
| 2 | CYTOSKELETON | 59 | 1967 | 5.378e-07 | 0.000157 |
| 3 | CYTOSKELETAL PART | 46 | 1436 | 2.106e-06 | 0.0002546 |
| 4 | MICROTUBULE | 21 | 405 | 1.567e-06 | 0.0002546 |
| 5 | SYNAPSE | 30 | 754 | 2.455e-06 | 0.0002546 |
| 6 | MEMBRANE REGION | 39 | 1134 | 2.616e-06 | 0.0002546 |
| 7 | NEURON PROJECTION | 34 | 942 | 4.348e-06 | 0.0003627 |
| 8 | CELL PROJECTION | 52 | 1786 | 6.785e-06 | 0.0004953 |
| 9 | MICROTUBULE CYTOSKELETON | 36 | 1068 | 1.02e-05 | 0.0006617 |
| 10 | NEURON PART | 40 | 1265 | 1.422e-05 | 0.0008306 |
| 11 | ACTIN CYTOSKELETON | 20 | 444 | 2.207e-05 | 0.001172 |
| 12 | CORTICAL ACTIN CYTOSKELETON | 7 | 58 | 3.068e-05 | 0.00128 |
| 13 | ANCHORING JUNCTION | 21 | 489 | 2.785e-05 | 0.00128 |
| 14 | MAIN AXON | 7 | 58 | 3.068e-05 | 0.00128 |
| 15 | MEMBRANE MICRODOMAIN | 15 | 288 | 4.709e-05 | 0.001833 |
| 16 | EXCITATORY SYNAPSE | 12 | 197 | 6.14e-05 | 0.002241 |
| 17 | SYNAPSE PART | 23 | 610 | 8.627e-05 | 0.002964 |
| 18 | CONTRACTILE FIBER | 12 | 211 | 0.0001182 | 0.003835 |
| 19 | PLASMA MEMBRANE REGION | 30 | 929 | 0.000125 | 0.003843 |
| 20 | CELL SUBSTRATE JUNCTION | 17 | 398 | 0.0001723 | 0.005032 |
| 21 | CORTICAL CYTOSKELETON | 7 | 81 | 0.000262 | 0.007285 |
| 22 | SARCOPLASMIC RETICULUM MEMBRANE | 5 | 38 | 0.0002858 | 0.007292 |
| 23 | CATION CHANNEL COMPLEX | 10 | 167 | 0.0002872 | 0.007292 |
Over-represented Pathway
| Num | Pathway | Pathview | Overlap | Size | P Value | Adj. P Value |
|---|---|---|---|---|---|---|
| 1 | MAPK_signaling_pathway_hsa04010 | 16 | 295 | 1.609e-05 | 0.0008365 | |
| 2 | PI3K_Akt_signaling_pathway_hsa04151 | 16 | 352 | 0.0001319 | 0.003029 | |
| 3 | Autophagy_animal_hsa04140 | 9 | 128 | 0.0001747 | 0.003029 | |
| 4 | Rap1_signaling_pathway_hsa04015 | 11 | 206 | 0.0003877 | 0.003785 | |
| 5 | Gap_junction_hsa04540 | 7 | 88 | 0.0004362 | 0.003785 | |
| 6 | Phospholipase_D_signaling_pathway_hsa04072 | 9 | 146 | 0.0004648 | 0.003785 | |
| 7 | Sphingolipid_signaling_pathway_hsa04071 | 8 | 118 | 0.0005095 | 0.003785 | |
| 8 | Oocyte_meiosis_hsa04114 | 8 | 124 | 0.000708 | 0.004505 | |
| 9 | Hedgehog_signaling_pathway_hsa04340 | 5 | 47 | 0.0007796 | 0.004505 | |
| 10 | Ras_signaling_pathway_hsa04014 | 11 | 232 | 0.001038 | 0.005399 | |
| 11 | Apelin_signaling_pathway_hsa04371 | 8 | 137 | 0.001353 | 0.006394 | |
| 12 | Calcium_signaling_pathway_hsa04020 | 9 | 182 | 0.002195 | 0.009512 | |
| 13 | Cellular_senescence_hsa04218 | 8 | 160 | 0.003561 | 0.01424 | |
| 14 | HIF_1_signaling_pathway_hsa04066 | 6 | 100 | 0.004659 | 0.01731 | |
| 15 | Adherens_junction_hsa04520 | 5 | 72 | 0.005197 | 0.01801 | |
| 16 | Signaling_pathways_regulating_pluripotency_of_stem_cells_hsa04550 | 7 | 139 | 0.006021 | 0.01957 | |
| 17 | Notch_signaling_pathway_hsa04330 | 4 | 48 | 0.006446 | 0.01972 | |
| 18 | Wnt_signaling_pathway_hsa04310 | 7 | 146 | 0.007814 | 0.02257 | |
| 19 | TGF_beta_signaling_pathway_hsa04350 | 5 | 84 | 0.009875 | 0.02682 | |
| 20 | Hippo_signaling_pathway_hsa04390 | 7 | 154 | 0.01031 | 0.02682 | |
| 21 | AMPK_signaling_pathway_hsa04152 | 6 | 121 | 0.0115 | 0.02846 | |
| 22 | cAMP_signaling_pathway_hsa04024 | 8 | 198 | 0.01231 | 0.02909 | |
| 23 | cGMP_PKG_signaling_pathway_hsa04022 | 7 | 163 | 0.01377 | 0.03092 | |
| 24 | Apoptosis_multiple_species_hsa04215 | 3 | 33 | 0.01427 | 0.03092 | |
| 25 | Apoptosis_hsa04210 | 6 | 138 | 0.02072 | 0.0431 | |
| 26 | Cytokine_cytokine_receptor_interaction_hsa04060 | 9 | 270 | 0.02545 | 0.0509 | |
| 27 | TNF_signaling_pathway_hsa04668 | 5 | 108 | 0.0265 | 0.05104 | |
| 28 | Focal_adhesion_hsa04510 | 7 | 199 | 0.03593 | 0.06672 | |
| 29 | Jak_STAT_signaling_pathway_hsa04630 | 6 | 162 | 0.04078 | 0.07152 | |
| 30 | ErbB_signaling_pathway_hsa04012 | 4 | 85 | 0.04316 | 0.07152 | |
| 31 | Regulation_of_actin_cytoskeleton_hsa04810 | 7 | 208 | 0.04386 | 0.07152 | |
| 32 | Cell_cycle_hsa04110 | 5 | 124 | 0.04401 | 0.07152 | |
| 33 | NF_kappa_B_signaling_pathway_hsa04064 | 4 | 95 | 0.06034 | 0.09507 | |
| 34 | Phosphatidylinositol_signaling_system_hsa04070 | 4 | 99 | 0.06808 | 0.1041 | |
| 35 | Hippo_signaling_pathway_multiple_species_hsa04392 | 2 | 29 | 0.07393 | 0.109 | |
| 36 | Cell_adhesion_molecules_.CAMs._hsa04514 | 5 | 145 | 0.07548 | 0.109 | |
| 37 | Necroptosis_hsa04217 | 5 | 164 | 0.1121 | 0.1576 | |
| 38 | ECM_receptor_interaction_hsa04512 | 3 | 82 | 0.1346 | 0.1842 | |
| 39 | FoxO_signaling_pathway_hsa04068 | 4 | 132 | 0.1493 | 0.1991 | |
| 40 | mTOR_signaling_pathway_hsa04150 | 4 | 151 | 0.2073 | 0.2695 | |
| 41 | p53_signaling_pathway_hsa04115 | 2 | 68 | 0.2843 | 0.3605 | |
| 42 | Endocytosis_hsa04144 | 5 | 244 | 0.328 | 0.4061 | |
| 43 | Neuroactive_ligand_receptor_interaction_hsa04080 | 5 | 278 | 0.4322 | 0.5226 | |
| 44 | Tight_junction_hsa04530 | 3 | 170 | 0.4922 | 0.5688 |
lncRNA-mediated sponge
| Num | lncRNA | miRNAs | miRNAs count | Gene | Sponge regulatory network | lncRNA log2FC | lncRNA pvalue | Gene log2FC | Gene pvalue | lncRNA-gene Pearson correlation |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | LINC00702 | hsa-miR-129-5p;hsa-miR-148a-3p;hsa-miR-148a-5p;hsa-miR-2110;hsa-miR-301a-3p;hsa-miR-30b-5p;hsa-miR-30c-5p;hsa-miR-30d-5p;hsa-miR-378a-5p;hsa-miR-421;hsa-miR-425-5p;hsa-miR-590-3p;hsa-miR-942-5p | 13 | SERPINE1 | Sponge network | -2.704 | 0 | -0.393 | 0.37043 | 0.395 |
| 2 | RP11-166D19.1 | hsa-miR-129-5p;hsa-miR-148a-3p;hsa-miR-148a-5p;hsa-miR-2110;hsa-miR-301a-3p;hsa-miR-378a-5p;hsa-miR-421;hsa-miR-425-5p;hsa-miR-590-3p;hsa-miR-942-5p | 10 | SERPINE1 | Sponge network | -3.855 | 0 | -0.393 | 0.37043 | 0.395 |
| 3 | MAGI2-AS3 | hsa-miR-2110;hsa-miR-301a-3p;hsa-miR-30b-5p;hsa-miR-30c-5p;hsa-miR-30d-5p;hsa-miR-378a-5p;hsa-miR-421;hsa-miR-425-5p;hsa-miR-590-3p;hsa-miR-769-5p;hsa-miR-942-5p | 11 | SERPINE1 | Sponge network | -2.414 | 0 | -0.393 | 0.37043 | 0.319 |
| 4 | RP11-536K7.3 | hsa-miR-129-5p;hsa-miR-2110;hsa-miR-301a-3p;hsa-miR-30b-5p;hsa-miR-30c-5p;hsa-miR-30d-5p;hsa-miR-378a-5p;hsa-miR-590-3p;hsa-miR-769-5p;hsa-miR-942-5p | 10 | SERPINE1 | Sponge network | -0.673 | 0.17143 | -0.393 | 0.37043 | 0.296 |